Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;5(2):239-47.
doi: 10.1002/cam4.587. Epub 2015 Dec 29.

Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction

Affiliations

Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction

Jay Chouhan et al. Cancer Med. 2016 Feb.

Abstract

Malignant small bowel obstruction (MSBO) that does not resolve with conservative measures frequently leaves few treatment options other than palliative care. This single-institution retrospective study assesses the outcomes of a more aggressive approach-concurrent systemic chemotherapy and total parenteral nutrition (TPN)-in the treatment of MSBO. The MD Anderson pharmacy database was queried to identify patients who received concurrent systemic chemotherapy and TPN between 2005 and 2013. Only patients with MSBO secondary to peritoneal carcinomatosis requiring TPN for ≥8 days were included. Survival and multivariate analyses were performed using the Kaplan-Meier method and Cox proportional hazard models. The study included 82 patients. MSBO resolution was observed in 10 patients. Radiographic assessments showed a response to chemotherapy in 19 patients; 6 of these patients experienced MSBO resolution. Patients spent an average of 38% of their remaining lives hospitalized, and 28% of patients required admission to the intensive care unit. In multivariate modeling, radiographic response to chemotherapy correlated with MSBO resolution (odds ratio [OR] 6.81; 95% confidence interval [CI], 1.68-27.85, P = 0.007). Median overall survival (OS) was 3.1 months, and the 1-year OS rate was 12.6%. Radiographic response to chemotherapy (HR 0.30; 95% CI, 0.16-0.56, P < 0.001), and initiation of new chemotherapy during TPN (HR 0.55; 95% CI, 0.33-0.94, P = 0.026) independently predicted for longer OS. Concurrent treatment with systemic chemotherapy and TPN for persistent MSBO results in low efficacy and a high morbidity and mortality, and thus should not represent a standard approach.

Keywords: Chemotherapy; gastrointestinal neoplasms; intestinal obstruction; ovarian neoplasms; survival analysis; total parenteral nutrition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Malignant small bowel obstruction (MSBO) resolution stratified by tumor response and treatment variables. TPN, total parenteral nutrition.
Figure 2
Figure 2
Overall survival (OS) for (A) all patients (n = 82) and (B) patients who underwent radiographic tumor assessment (n = 54).

References

    1. Ripamonti, C. , and Bruera E.. 2002. Palliative management of malignant bowel obstruction. Int. J. Gynecol. Cancer 12: 135–143. - PubMed
    1. Feuer, D. J. , Broadley K. E., Shepherd J. H., and Barton D. P.. 2000. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst. Rev. CD002764. - PubMed
    1. Feuer, D. J. , Broadley K. E., Shepherd J. H., and Barton D. P.. 1999. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. The systematic review steering committee. Gynecol. Oncol. 75: 313–322. - PubMed
    1. Larson, J. E. , Podczaski E. S., Manetta A., Whitney C. W., and Mortel R.. 1989. Bowel obstruction in patients with ovarian carcinoma: analysis of prognostic factors. Gynecol. Oncol. 35: 61–65. - PubMed
    1. Turnbull, A. D. , Guerra J., and Starnes H. F.. 1989. Results of surgery for obstructing carcinomatosis of gastrointestinal, pancreatic, or biliary origin. J. Clin. Oncol. 7: 381–386. - PubMed

MeSH terms